TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SF7UUV9
| Market Closed - Deutsche Boerse AG 03:39:19 2024-05-10 pm EDT | ||
| 23.35 EUR | +0.99% |
|
| Current month | +11.35% | ||
| 1 month | +9.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 23.35 | +0.99% | 0 |
| 24-05-09 | 23.12 | -0.90% | 0 |
| 24-05-08 | 23.33 | +4.71% | 0 |
| 24-05-07 | 22.28 | +3.10% | 0 |
| 24-05-06 | 21.61 | +0.51% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 03:39 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UUV |
| ISIN | DE000SF7UUV9 |
| Date issued | 2021-08-18 |
| Strike | 173.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.89 € |
|---|---|
| Lowest since issue | 2.92 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8
USD
Average target price
462.1
USD
Spread / Average Target
+9.30%
- Stock Market
- Certificates
- Certificat
